These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21841250)

  • 61. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients.
    Sancesario GM; Cencioni MT; Esposito Z; Borsellino G; Nuccetelli M; Martorana A; Battistini L; Sorge R; Spalletta G; Ferrazzoli D; Bernardi G; Bernardini S; Sancesario G
    J Alzheimers Dis; 2012; 31(4):865-78. PubMed ID: 22717612
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
    Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
    CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
    [TBL] [Abstract][Full Text] [Related]  

  • 64. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Leuzy A; Ashton NJ; Mattsson-Carlgren N; Dodich A; Boccardi M; Corre J; Drzezga A; Nordberg A; Ossenkoppele R; Zetterberg H; Blennow K; Frisoni GB; Garibotto V; Hansson O
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2121-2139. PubMed ID: 33674895
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid.
    Voyle N; Patel H; Folarin A; Newhouse S; Johnston C; Visser PJ; Dobson RJ; Kiddle SJ;
    J Alzheimers Dis; 2017; 55(4):1417-1427. PubMed ID: 27834776
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
    Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Associations of Alcohol Consumption with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
    Wang ZT; Li KY; Tan CC; Xu W; Shen XN; Cao XP; Wang P; Bi YL; Dong Q; Tan L; Yu JT
    J Alzheimers Dis; 2021; 82(3):1045-1054. PubMed ID: 34151793
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum.
    Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL
    J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.
    Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S
    Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
    Bridel C; Hoffmann T; Meyer A; Durieux S; Koel-Simmelink MA; Orth M; Scheltens P; Lues I; Teunissen CE
    Alzheimers Res Ther; 2017 Jun; 9(1):38. PubMed ID: 28587659
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate.
    Edsbagge M; Andreasson U; Ambarki K; Wikkelsø C; Eklund A; Blennow K; Zetterberg H; Tullberg M
    J Alzheimers Dis; 2017; 58(3):821-828. PubMed ID: 28505972
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease.
    Biscetti L; Salvadori N; Farotti L; Cataldi S; Eusebi P; Paciotti S; Parnetti L
    Clin Chim Acta; 2019 Jul; 494():71-73. PubMed ID: 30844364
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease.
    Jaillard A; Vanhoutte M; Maureille A; Schraen S; Skrobala E; Delbeuck X; Rollin-Sillaire A; Pasquier F; Bombois S; Semah F
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):324-333. PubMed ID: 30155553
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cerebrospinal Fluid Biomarkers in Idiopathic Normal Pressure Hydrocephalus versus Alzheimer's Disease and Subcortical Ischemic Vascular Disease: A Systematic Review.
    Manniche C; Hejl AM; Hasselbalch SG; Simonsen AH
    J Alzheimers Dis; 2019; 68(1):267-279. PubMed ID: 30741681
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Salivary Aβ
    Fan Z; Li Z; Zhao S; Chen Y; Su Y; Peng G; Luo B
    J Neurol; 2023 Apr; 270(4):1945-1954. PubMed ID: 36562850
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
    Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
    J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.